Last updated on September 2017

Tralokinumab monotherapy for moderate to severe atopic dermatitis.


Brief description of study

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Detailed Study Description

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Clinical Study Identifier: TX152426

Contact Investigators or Research Sites near you

Start Over

Jenna Spatz

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.